[1]
|
Ganti, A.K., Klein, A.B., Cotarla, I., Seal, B. and Chou, E. (2021) Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients with Non-Small Cell Lung Cancer in the US. JAMA Oncology, 7, 1824-1832.
https://doi.org/10.1001/jamaoncol.2021.4932
|
[2]
|
Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[3]
|
Nestle, U., Adebahr, S., Kaier, K., Gkika, E., Schimek-Jasch, T., Hechtner, M., et al. (2020) Quality of Life after Pulmonary Stereo-tactic Fractionated Radiotherapy (SBRT): Results of the Phase II STRIPE Trial. Radiotherapy and Oncology, 148, 82-88. https://doi.org/10.1016/j.radonc.2020.03.018
|
[4]
|
Chi, A. and Nguyen, N.P. (2022) Rationale for Combing Stere-otactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer. Cancers, 14, Article 3144.
https://doi.org/10.3390/cancers14133144
|
[5]
|
Plá, M., Beltrán, D.D. and Albiach, E.F. (2021) Immune Check-points Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Re-view. International Journal of Molecular Sciences, 22, Article 11621. https://doi.org/10.3390/ijms222111621
|
[6]
|
Abdulhaleem, M., et al. (2022) Local Control Outcomes for Combina-tion of Stereotactic Radiosurgery and Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases. Journal of Neuro-Oncology, 157, 101-107.
https://doi.org/10.1007/s11060-022-03951-7
|
[7]
|
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639.
https://doi.org/10.1056/NEJMoa1507643
|
[8]
|
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
|
[9]
|
Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q.M., Burgio, M.A., de Castro Carpeno, J., et al. (2021) Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733.
https://doi.org/10.1200/JCO.20.01605
|
[10]
|
Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., et al. (2019) Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 14, 867-875. https://doi.org/10.1016/j.jtho.2019.01.006
|
[11]
|
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211.
https://doi.org/10.1016/S1470-2045(20)30641-0
|
[12]
|
Brahmer, J.R., Lee, J.-S., Ciuleanu, T.-E., Bernabe Caro, R., Nishio, M., Urban, L., et al. (2023) Five-Year Survival Outcomes with Nivolumab plus Ipilimumab versus Chemother-apy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503
|
[13]
|
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
|
[14]
|
Jassem, J., de Marinis, F., Giaccone, G., Vergnenegre, A., Barrios, C.H., Morise, M., et al. (2021) Updated Overall Survival Analysis from IMpower110: Ate-zolizumab versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. Journal of Thoracic Oncology, 16, 1872-1882.
https://doi.org/10.1016/j.jtho.2021.06.019
|
[15]
|
Socinski, M.A., et al. (2023) Association of Immune-Related Ad-verse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535. https://doi.org/10.1001/jamaoncol.2022.7711
|
[16]
|
Socinski, M.A., Nishio, M., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., et al. (2021) IMpower150 Final Overall Survival Analyses for Atezolizumab plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology, 16, 1909-1924. https://doi.org/10.1016/j.jtho.2021.07.009
|
[17]
|
Yang, Y., Sun, J., Wang, Z., Fang, J., Yu, Q., Han, B., et al. (2021) Updated Overall Survival Data and Predictive Biomarkers of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Journal of Thoracic Oncology 16, 2109-2120.
https://doi.org/10.1016/j.jtho.2021.07.015
|
[18]
|
Zhou, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Chen, G., et al. (2021) Sintilimab plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Re-sults from a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 16, 1501-1511. https://doi.org/10.1016/j.jtho.2021.04.011
|
[19]
|
Zhou, .F, Qiao, M. and Zhou, C. (2021) The Cutting-Edge Progress of Immune-Checkpoint Blockade in Lung Cancer. Cellular & Molecular Immunology, 18, 279-293. https://doi.org/10.1038/s41423-020-00577-5
|
[20]
|
MacManus, M. and Hegi-Johnson, F. (2022) Overcoming Im-munotherapy Resistance in NSCLC. The Lancet Oncology, 23, 191-193. https://doi.org/10.1016/S1470-2045(21)00711-7
|
[21]
|
Barbari, C., et al., (2020) Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 21, Article 5009. https://doi.org/10.3390/ijms21145009
|
[22]
|
Wu, G., Baine, M.J., Zhao, N., Li, S., Li, X. and Lin, C. (2019) Lym-phocyte-Sparing Effect of Stereotactic Body Radiation Therapy Compared to Conventional Fractionated Radiation Ther-apy in Patients with Locally Advanced Pancreatic Cancer. BMC Cancer, 19, Article No. 977. https://doi.org/10.1186/s12885-019-6220-1
|
[23]
|
Chen, D., Verma, V., Patel, R.R., Barsoumian, H.B., Cortez, M.A. and Welsh, J.W. (2020) Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. International Journal of Radiation Oncology, Biology, Physics, 108, 196-203.
https://doi.org/10.1016/j.ijrobp.2020.01.032
|
[24]
|
Theelen, W.S.M.E., Chen, D., Verma, V., Hobbs, B.P., Peulen, H.M.U., Aerts, J.G.J.V., et al. (2021) Pembrolizumab with or without Radiotherapy for Metastatic Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials. The Lancet Respiratory Medicine, 9, 467-475. https://doi.org/10.1016/S2213-2600(20)30391-X
|
[25]
|
Schoenfeld, J.D., Giobbie-Hurder, A., Ranasinghe, S., Kao, K.Z., Lako, A., Tsuji, J., et al. (2022) Durvalumab plus Tremelimumab Alone or in Combination with Low-Dose or Hypofractionated Radiotherapy in Metastatic Non-Small- Cell Lung Cancer Refractory to Previous PD(L)-1 Therapy: An Open-Label, Multicentre, Randomised, Phase 2 Trial. The Lancet Oncology, 23, 279-291. https://doi.org/10.1016/S1470-2045(21)00658-6
|
[26]
|
Bestvina, C.M., Pointer, K.B., Karrison, T., Al-Hallaq, H., Hoffman, P.C., Jelinek, M.J., et al. (2022) A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV NSCLC Study. Journal of Thoracic Oncology, 17, 130-140. https://doi.org/10.1016/j.jtho.2021.08.019
|
[27]
|
Welsh, J., Menon, H., Chen, D., Verma, V., Tang, C., Altan, M., et al. (2020) Pembrolizumab with or without Radiation Therapy for Metastatic Non-Small Cell Lung Cancer: A Random-ized Phase I/II Trial. The Journal for ImmunoTherapy of Cancer, 8, e001001. https://doi.org/10.1136/jitc-2020-001001
|
[28]
|
Menon, H., Chen, D., Ramapriyan, R., Verma, V., Barsoumian, H.B., Cushman, T.R., et al. (2019) Influence of Low- Dose Radiation on Abscopal Responses in Patients Receiving High-Dose Radiation and Immunotherapy. The Journal for ImmunoTherapy of Cancer, 7, 237. https://doi.org/10.1186/s40425-019-0718-6
|
[29]
|
Yin, L., Xue, J., Li, R., Zhou, L., Deng, L., Chen, L., et al. (2020) Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients with Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 108, 212-224.
https://doi.org/10.1016/j.ijrobp.2020.05.002
|
[30]
|
Westcott, P.M.K., et al. (2023) Mismatch Repair Deficiency Is Not Sufficient to Elicit Tumor Immunogenicity. Nature Genetics, 55, 1686-1695. https://doi.org/10.1038/s41588-023-01499-4
|
[31]
|
Dovedi, S.J., Adlard, A.L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E.J., et al. (2014) Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research, 74, 5458- 5468. https://doi.org/10.1158/0008-5472.CAN-14-1258
|
[32]
|
Twyman-Saint, V.C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377.
https://doi.org/10.1038/nature14292
|
[33]
|
Anscher, M.S., Arora, S., Weinstock, C., Amatya, A., Bandaru, P., Tang, C., et al. (2022) Association of Radiation Therapy with Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database. JAMA Oncology, 8, 232-240. https://doi.org/10.1001/jamaoncol.2021.6439
|
[34]
|
Maher, V.E., Fernandes, L.L., Weinstock, C., Tang, S., Agarwal, S., Brave, M., et al. (2019) Analysis of the Association between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. Journal of Clinical Oncology, 37, 2730-2737. https://doi.org/10.1200/JCO.19.00318
|
[35]
|
Weichselbaum, R.R. (2018) The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment. Journal of Clinical Oncology, 36, 3240-3250. https://doi.org/10.1200/JCO.18.00847
|
[36]
|
Brooks, E.D. and Chang, J.Y. (2019) Time to Abandon Single-Site Ir-radiation for Inducing Abscopal Effects. Nature Reviews Clinical Oncology, 16, 123-135. https://doi.org/10.1038/s41571-018-0119-7
|
[37]
|
Pitroda, S.P., Khodarev, N.N., Huang, L., Uppal, A., Wightman, S.C., Ganai, S., et al. (2018) Integrated Molecular Subtyping Defines a Curable Oligometastatic State in Colorectal Liver Metastasis. Nature Communications, 9, Article No. 1793. https://doi.org/10.1038/s41467-018-04278-6
|
[38]
|
Hegde, P.S., Karanikas, V. and Evers, S. (2016) The Where, the When, and the How of Immune Monitoring for Cancer Immu-notherapies in the Era of Checkpoint Inhibition. Clinical Cancer Research, 22, 1865-1874.
https://doi.org/10.1158/1078-0432.CCR-15-1507
|
[39]
|
Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548.
https://doi.org/10.1038/nature25501
|
[40]
|
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.C., Va-lidire, P., Trautmann, A., et al. (2012) Matrix Architecture Defines the Preferential Localization and Migration of T Cells into the Stroma of Human Lung Tumors. Journal of Clinical Investigation, 122, 899-910. https://doi.org/10.1172/JCI45817
|
[41]
|
Ene-Obong, A., Clear, A.J., Watt, J., Wang, J., Fatah, R., Riches, J.C., et al. (2013) Activated Pancreatic Stellate Cells Sequester CD8+ T Cells to Reduce Their Infiltration of the Juxtatumoral Com-partment of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 145, 1121-1132. https://doi.org/10.1053/j.gastro.2013.07.025
|
[42]
|
Arina, A., Idel, C., Hyjek, E.M., Alegre, M.L., Wang, Y., Bin-dokas, V.P., et al. (2016) Tumor-Associated Fibroblasts Predominantly Come from Local and Not Circulating Precursors. Proceedings of the National Academy of Sciences of the United States of America, 113, 7551-7556. https://doi.org/10.1073/pnas.1600363113
|
[43]
|
Dominguez, C.X., Muller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., et al. (2019) Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. Cancer Discovery, 10, 232-253. https://doi.org/10.1158/2159-8290.CD-19-0644
|
[44]
|
Yost, K.E., Satpathy, A.T., Wells, D.K., Qi, Y., Wang, C., Kageyama, R., et al. (2019) Clonal Replacement of Tumor-Specific T Cells Following PD-1 Blockade. Nature Medicine, 25, 1251-5799.
https://doi.org/10.1038/s41591-019-0522-3
|